Global Blood Therapeutics

Healthcare  |  Biotechnology
55.25 0.0 0.0%
Stock Price | Nov. 19, 2019, 4 p.m.
Bid: 0.0
Ask: 0.0
Prev. Close: 55.25
52 Week Low: 30.15
52 Week High: 64.94
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Read more Read less

Recently Viewed Tickers

Premium Stock Watchlist 11/04/2015

4 years ago